Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study.
Mingxia JiangBin ShaoDonggui WanJiaxuan LiuMaiyue HeYue ChaiDie SangJiayu WangZongbi YiYing FanPeng YuanBing-He XuQiao LiPublished in: Therapeutic advances in medical oncology (2023)
The results suggest that eribulin combined with antiangiogenic therapy has a meaningful clinical activity and an acceptable safety profile in HER2-negative MBC.